RxDoctor Payments Data

Patrick Perkins, MD

Pulmonary Disease · Kansas City, MONPI 1437159308

Payments from drug & device makers

$8,409in general payments, 2019–2025

Across 53 payments — averaging $158.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Olympus Corporation Of The Americas$690
  • GSK$165
  • AstraZeneca$150
  • Boehringer Ingelheim$120
  • Genentech USA, Inc.$84
  • plus $147 from 6 others

What the payments were for

  • Travel & lodging$6908%
  • Food & beverage$6688%
  • Education$7,05284%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,409 in reported general payments places this provider in the 70th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$524,577
Medicare patients
432
Services billed
10,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter260$216,818
NucalaMepolizumab23$81,220
Spiriva RespimatTiotropium Bromide96$71,385
Breo ElliptaFluticasone/Vilanterol80$37,983
Spiriva HandihalerTiotropium Bromide33$34,352
XolairOmalizumab16$32,702
Stiolto RespimatTiotropium Br/Olodaterol Hcl32$23,986
SymbicortBudesonide/Formoterol Fumarate57$22,920
Incruse ElliptaUmeclidinium Bromide46$17,604
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate62$16,572
DuleraMometasone/Formoterol30$16,141
XareltoRivaroxaban20$13,284
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$10,725
Fluticasone-SalmeterolFluticasone Propion/Salmeterol46$8,861
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$165$364,349423 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$120$95,371128 claims
AstraZenecaSymbicort, Breztri Aerosphere$150$31,48471 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →